Sanofi offers its tender for Genzyme

Sanofi offers its tender for Genzyme

There has been a lot happening in the proposed deal between Sanofi-Aventis and Genzyme and in the latest turn of events, Sanofi, the French drug company has said that it will be extending its tender to Genzyme. This would be done, it said, despite presence of 'significant' differences between the two parties.

Sanofi has also reiterated that the offer is not going to see an increase in bidding price. At present, the tender offer stands at $69 per share to which the board of director of Genzyme has already given its negative response. As per the Boston Global this bidding price is just done so that there is some pressure built on board of Genzyme.

Most important and pivotal point of discussions between the two companies is the value of the drug called Lemtrada. This drug is being developed by Genzyme.

Sanofi in its statement has said that there are significant differences in the potential of the drug and that is why they are not able to decide on any one thing.

On Friday, share price of Genzyme was at $71.58 per share at the Nasdaq exchange.


FrenchTribune Specials

Sleep Apnea Increases Risk of Cancer

A recent study has revealed that sleep apnea might tend to be the reason for raising the risk of cancer. This has been recently found in a research done by scientists who have found that when a person is affectedly sleep apnea, it has all the...

Romney’s Strategies to Win Votes Not Helping Him Enough

As the US presidential elections are gearing up, Mitt Romney has turned aggressive with his campaign strategies. However, while campaigning, he needs to keep a few points in minds. In all of his campaigns, he has making repeated mistakes which...

Poll

Can Greece Come out of Economic Problems: